EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Age, Age‐Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation‐Wide Retrospective Cohort Study

Blair Rajamaki, Olli Tenhunen iD, Liisa Pylkkänen, Thuan Vo iD, Anne Paakinaho iD, Miia Turpeinen, Sirpa Hartikainen, Anna-Maija Tolppanen iD

Pharmacoepidemiology and Drug Safety · 2026-07 · 35 (7)

DOI: 10.1002/pds.70416 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 16.06.2026. Verfasst von Blair Rajamaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Eastern Finland, Kuopio, Finland. Hauptthemen laut MEDLINE: Breast Neoplasms, Aminopyridines, Piperazines, Purines. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Strategic Research Council Finland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Prevalence of breast cancer (BC) increases with age, but the external validity of data obtained from pivotal trials of medicinal products remains a concern due to the underrepresentation of frail and older adults. Cyclin‐dependent kinase inhibitors (CDKi), palbociclib, abemaciclib, and ribociclib are considered an essential part of the standard‐of‐care in the management of advanced/metastatic breast cancer. We investigated age, comorbidities, and survival in a nationwide real‐world cohort of CDKi users.

Methods

Data from the Finnish Cancer Registry, reimbursed dispensed prescriptions, Electronic Prescription Database, Care Register for Health Care (CRHC), and Causes of Death Register were combined and analysed.

Results

Altogether 1921 women with BC initiated CDKi treatment in 2018–2022. The median age at initiation was 66.9 years, with 43.2% of the study cohort being < 65 years of age, 36.1% 65–74 years, 19.0% 75–84 years, and 1.7% 85 years or older. The prevalence of age or frailty‐related comorbidities in individuals ≥ 65 years was low, highest for cardiovascular diseases, 32.3%, and diabetes, 16.9%. The median survival was 25.3 months, with longer median survival times in younger age groups (27.7 months in < 65 year‐olds, 25.1 months in aged 65–74, 21.4 months in aged 75–84 years, and 15.4 months in 85 years or older).

Conclusions

Real‐world CDKi users are older than women included in the pivotal trials, and the survival differences between age groups imply challenges in the generalisability of data from pivotal trials. The real‐world CDKi user population is characterised by a low prevalence of major comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAminopyridinesPiperazinesPurinesPyridinesHumansFemaleAgedRetrospective StudiesAged, 80 and overAge FactorsComorbidityFinlandRegistriesMiddle AgedProtein Kinase InhibitorsCohort StudiesAntineoplastic AgentsPrevalenceBenzimidazoles

Stichwörter der Autor:innen

anti‐cancer drugsbreast cancergeriatric medicinepharmacoepidemiologyprescribing

Substanzen

AminopyridinesribociclibPiperazinespalbociclibPurinesPyridinesabemaciclibProtein Kinase InhibitorsAntineoplastic AgentsBenzimidazoles

Autor:innen und Institutionen

  • School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
  • Finnish Medicines Agency, Helsinki, Finland.
  • Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland.
  • Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland.

ORCID-Profile: Olli Tenhunen, Thuan Vo, Anne Paakinaho, Anna-Maija Tolppanen

Förderung

  • Strategic Research Council Finland

Zitieren

APA

Rajamaki, B., Tenhunen, O., Pylkkänen, L., Vo, T., Paakinaho, A., Turpeinen, M., Hartikainen, S., & Tolppanen, A. M. (2026). Age, Age‐Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation‐Wide Retrospective Cohort Study. Pharmacoepidemiology and Drug Safety, 35(7). https://doi.org/10.1002/pds.70416

Vancouver

Rajamaki B, Tenhunen O, Pylkkänen L, Vo T, Paakinaho A, Turpeinen M, et al. Age, Age‐Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation‐Wide Retrospective Cohort Study. Pharmacoepidemiology and Drug Safety. 2026;35(7). doi:10.1002/pds.70416

BibTeX
@article{Rajamaki2026,
  author = {Rajamaki, Blair and Tenhunen, Olli and Pylkkänen, Liisa and Vo, Thuan and Paakinaho, Anne and Turpeinen, Miia and Hartikainen, Sirpa and Tolppanen, Anna-Maija},
  title = {Age, Age‐Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation‐Wide Retrospective Cohort Study},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  volume = {35},
  number = {7},
  doi = {10.1002/pds.70416}
}
Kostenlos starten →